Edwards Lifesciences (EW) Q2 2026 Earnings Beat Driven by 48% Surge in Mitral and Tricuspid Therapies
As seen on the 24/7 Wall St. homepage on July 23, 2026.
Edwards Lifesciences beat Q2 earnings on the back of a 48% surge in mitral and tricuspid therapies, and raised full-year sales guidance to 10%-11% growth as TAVR durability data and a pending Medicare decision unlock new patient pools.
Continue ReadingShow less
Edwards Lifesciences reported Q2 2026 earnings per share of $0.78, topping the consensus estimate of $0.74 by roughly 5%. Revenue came in at $1.74 billion, beating expectations of $1.70 billion by about 2.4% and marking a clear step up from the $1.65 billion the company posted in Q1 2026. The standout driver was the mitral and tricuspid therapies segment, which surged 48% in the quarter.
The company used the strong results to raise its full-year sales guidance to 10% to 11% growth. Management pointed to two specific catalysts expected to expand the patient pool going forward: new TAVR durability data and a pending Medicare coverage decision. Both developments matter because they could bring structural heart disease patients into the treatment funnel who were previously ineligible or cautious about pursuing the procedure.
Sponsored
_________________________________
What's Your Number...?
Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
Revenue has now climbed in each of the last four reported quarters, rising from $1.39 billion in Q2 2024 to $1.74 billion in Q2 2026. The consistency of that trend, combined with the guidance raise, suggests the mitral and tricuspid business has become a meaningful growth engine alongside the company's established TAVR franchise. The Medicare decision, once it arrives, will be a key data point for gauging how much of that prospective patient pool actually converts.
Mentioned: EW